動物用抗菌・抗生物質の世界市場規模：製品別、動物タイプ別、デリバリーモード別、地域別、2024年～2031年

動物用抗菌・抗生物質市場の評価、2024年～2031年

皮革や畜産物の消費需要の高まりは、健康な動物の個体数の増加とともに満足のいくものとなっています。従って、肉、ミルク、皮、その他のような動物製品の需要は、動物用抗菌・抗生物質市場に計り知れない成長の見通しを提供すると予測されています。これに加えて、動物の間で病気が多く蔓延していることも市場を活性化させる要因の一つです。動物用抗菌・抗生物質市場は、2023年に69億5,000万米ドルの収益を突破し、2031年には約117億5,000万米ドルの評価に達するまで成長を続ける。

世界人口の増加に伴い、肉、鶏肉、卵、乳製品などの動物性タンパク質源の需要が急増しています。このような需要の急増は、家禽飼育による動物個体数の増加を必要とし、その結果、感染症の有病率が高くなり、治療と予防のための抗生物質の必要性が高まる。このため、現在の市場は2024年から2031年にかけてCAGR約6.10%で大きく成長すると予測されています。

動物用抗菌・抗生物質市場定義/概要

動物用抗菌・抗生物質は、牛、コンパニオンアニマル、家禽の予防およびメタ予防段階にある細菌性疾患を治療するための治療法です。この治療法は、食用動物の細菌感染を減少させることにより、動物の健康を維持し、疾病の発生を予防し、食品の安全を確保するのに役立ちます。経口錠剤、注射剤、外用液、飼料添加物など、さまざまな形態があります。安全性、有効性、獣医療における正しい使用法を保証するため、政府当局がその製造と商品化を管理しています。

抗菌剤はその効果的な利点にもかかわらず、抗菌剤耐性に対する懸念から、大半の地域では使用が推奨されず、しばしば禁止されています。しかし、成長促進を目的とした抗菌薬の使用は、世界の一部の地域では依然として存在します。抗菌剤耐性に関する治療意識の高まりは、獣医師から処方された場合のみ抗生物質を使用し、治療の全コースを完了し、代替の予防策を検討することに重点を置いた、責任ある使用方法への転換を必要としています。また、動物における抗菌薬の過剰使用や誤用を抑制することを目的とした規制が世界的に進展しています。これはおそらく市場力学に影響を与え、責任ある使用方法の採用を促すであろう。

動物用抗菌・抗生物質市場の採用を促進する要因は？

人口増加と所得水準の増加は、肉、牛乳、卵を含む動物性タンパク質の需要を高めています。そのため、抗生物質を使用して細菌感染症や人獣共通感染症を予防・治療し、家畜や家禽の健康と生産性を維持する必要性が高まっています。

家畜はさまざまな細菌感染症にかかりやすく、健康や生産性に深刻な影響を及ぼす可能性があるため、集約的な畜産を実施する必要があります。そのため、畜産部門では、家畜や家禽の疾病発生のリスクを最小限に抑えるため、過密飼育やその他の環境ストレスを軽減することに主眼を置いています。

さらに、農家の死亡率や経済的損失を減らすために抗菌薬や抗生物質の使用が増加しており、市場に新たな機会の扉を開いています。動物福祉に関する消費者規制当局や業界利害関係者の意識の高まりは、倫理基準や規制要件を満たすように、食品生産のために飼育される動物の健康と福祉を確保することを強調しています。

同様に、動物の幸福と成長促進のためにこれらの治療法を使用することは、規制機関にとって問題であり、それによってメーカーが人間の健康への影響を最小限に抑えた環境に優しい医薬品を開発することを奨励しています。このような規制当局の支援は、動物用抗菌・抗生物質市場に新たな成長の道を提供すると予想されます。

さらに、ペットの飼育数の増加が動物の健康への投資を急増させ、コンパニオンアニマルの感染症治療に抗生物質が使用される可能性を後押ししています。

動物用抗菌・抗生物質市場の成長に影響を与える課題は？

動物における抗生物質の過剰使用や誤用による抗菌剤耐性（AMR）の拡大に関する懸念の高まりは、細菌が耐性を獲得し、その結果、既存の抗生物質がこれらの耐性株に対して効かなくなる可能性が高いです。耐性菌の治療は困難で費用もかかるため、これは動物と人間の健康に重大な脅威をもたらします。

処方された動物用医薬品の使用に対する政府の規制が世界的に変化していることは、世界企業にとって課題となっており、一部の地域では責任ある使用の実践を妨げています。

より安価な代替薬が入手可能になることで、その使用量が増加し、旧来の抗生物質に関連する耐性問題の持続に寄与すると予測されます。

さらに、農家、獣医師、ペットの飼い主の間で、抗生物質の責任ある使用に関する認識や教育が不十分であることが、抗生物質の採用をさらに妨げると思われます。同様に、動物の健康に有効で容易に入手できる抗生物質の代替品が限られていることも大きな課題です。新規抗菌薬や、ワクチンやバクテリオファージのような代替ソリューションの研究開発が進められているが、その普及には時間がかかりそうです。

目次

第1章 世界の動物用抗菌・抗生物質市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の動物用抗菌・抗生物質市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 動物用抗菌・抗生物質の世界市場：製品別

• 概要
• テトラサイクリン系抗生物質
• ペニシリン系
• スルホンアミド系
• マクロライド系
• その他

第6章 動物用抗菌・抗生物質の世界市場：動物タイプ別

• 概要
• コンパニオンアニマル
• 食料生産動物

第7章 動物用抗菌・抗生物質の世界市場：デリバリーモード別

• 概要
• 経口粉末剤
• 注射剤
• プレミックス

第8章 動物用抗菌・抗生物質の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の動物用抗菌・抗生物質市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第10章 企業プロファイル

• Zoetis
• Merck Animal Health
• Merial
• Elanco
• Bayer HealthCare
• Biogenesis Bago
• HUVEPHARMA
• Ceva Sante Animale
• Dechra Pharmaceuticals
• ECO Animal Health

第11章 企業プロファイル主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第12章 付録

• 関連調査

Animal Antibacterial And Antibiotics Market Valuation - 2024-2031

Growing demand for leather and animal products for consumption is satisfactory with an increase in the population of healthy animals. Thus, the demand for animal products such as meat, milk, skin, and others is projected to offer immense growth prospects to the Animal Antibacterial And Antibiotics Market. In addition to this, the high prevalence of diseases among animals is another factor enabling the market. Animal Antibacterial And Antibiotics Market surpassed a revenue of USD 6.95 Billion in 2023 and continue growing to reach a valuation of aroundUSD 11.75 Billion by 2031.

The global population is growing, leading to an upsurge in demand for animal-derived protein sources like meat, poultry, eggs, and dairy products. This spurring demand necessitates an increase in animal populations through poultry practices, resulting in a higher prevalence of infections and a greater need for antibiotics for treatment and prevention. Thus, the current market is projected to grow substantially at aCAGR of approximately 6.10% from 2024 to 2031.

Animal Antibacterial And Antibiotics Market: Definition/ Overview

Animal antibacterial and antibiotics are treatments designed to treat bacterial illnesses, which are in the prophylaxis and metaphylaxis stage, in cattle, companion animals, and poultry. This form of treatment helps preserve animal health, prevent disease outbreaks, and ensure food safety by reducing bacterial infections in food-producing animals. It is present in a variety of forms, including oral pills, injectables, topical solutions, and feed additives. The government authorities control their manufacturing and commercialization to assure their safety, effectiveness, and correct usage in veterinary care.

Despite its effective benefits, it is discouraged and often banned in the majority of the regions due to concerns about antimicrobial resistance. However, the use of antibacterials for growth promotion still exists in some parts of the world. Growing awareness about antimicrobial resistance necessitates a shift towards responsible use practices, emphasizing only using antibiotics when prescribed by a veterinarian, completing the full course of treatment, and exploring alternative preventive measures. Also, evolving regulations worldwide aim to inhibit the overuse and misuse of antimicrobials in animals. This will likely influence market dynamics and encourage the adoption of responsible use practices.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Which are the Drivers Encouraging the Adoption of Animal Antibacterial And Antibiotics Market?

Growing population growth and income levels is bolstering the demand for animal protein, including meat, milk, and eggs. Therefore, there is a greater need to maintain the health and productivity of livestock and poultry to prevent and treat bacterial infections or zoonotic diseases using antibiotics.

As the animals are highly susceptible to various bacterial infections that can seriously affect their health and productivity, there is need for need for implementing intensive animal farming practices. Thus, the animal husbandry sector is majorly focusing on lowering overcrowding and other environmental stress to minimize risks of disease outbreaks in livestock and poultry.

Additionally, the use of antibacterial drugs and antibiotics is increasing to reduce mortality and economic losses of farmers, opening new doors of opportunities for the market. The rise in awareness among consumers regulators and industry stakeholders about animal welfare emphasizes ensuring the health and welfare of animals raised for food production so as to meet ethical standards and regulatory requirements.

Similarly, the use of these treatments for the well-being as well as promoting growth of the animals is concerning the regulatory bodies, thereby encouraging the manufacturers to develop eco-friendly drugs with minimal impact on human health. This regulatory support is anticipated to offer new avenues of growth to the Animal Antibacterial And Antibiotics Market.

Furthermore, increased pet ownership is surging investments in animal health, thereby boosting the potential potential use of antibiotics for treating infections in companion animals.

What are the Challenges Impacting the Growth of the Animal Antibacterial And Antibiotics Market?

Growing concerns regarding the spread of antimicrobial resistance (AMR) due to the overuse and misuse of antibiotics in animals is likely to result in bacteria developing resistance, thus, rendering existing antibiotics ineffective against these resistant strains. This poses a significant threat to animal and human health, as treating the resistant bacterial infections is difficult as well as expensive.

Changing government regulations globally against the use of prescribed veterinary drugs is creating challenges for global companies and hindering responsible use practices in some regions.

The availability of cheaper alternative drugs is projected to increase its usage, thereby contributing to the persistence of resistance issues associated with older antibiotics.

Moreover, inadequate awareness and education among farmers, veterinarians, and pet owners regarding responsible antibiotic use will further hinder its adoption. Similarly, the limited availability of effective and readily available alternatives to antibiotics for animal health poses a huge challenge. While research and development efforts are underway for novel antimicrobials and alternative solutions like vaccines and bacteriophages, their widespread adoption is likely to take time.

Category-Wise Acumens

Which Delivery Mode helps in the Growth of the Animal Antibacterial And Antibiotics Market?

Oral administration is anticipated to hold a major in the market over the forecast period. The easy availability at affordable prices and convenience in the usage of oral drugs is projected to help the segment retain its top-notch position in the Animal Antibacterial And Antibiotics Market.

In addition to this, the option of mass medication in food-producing animals further enhances its use through feed and water additives.

Consequently, the choice of catering to different animal preferences and ease of administration in oral formulations, including powders, tablets, premixes, and medicated feed additives, further boosts the demand for these treatments in animal husbandry.

Will the Effectiveness of Tetracyclines Help Skyrocket the Sales of Animal Antibacterial and Antibiotics?

As per our analyst, the tetracyclines segment is projected to hold the largest market share globally. This dominance is primarily due to their broad-spectrum effectiveness and affordability.

Also, their well-established application in veterinary practices is another driving factor despite its increasing and long-lasting impact on the development of bacterial resistance.

Another widely used segment is penicillin, particularly owing to its effectiveness against specific bacterial infections in food-producing animals. However, its dominance might also be affected owing to the changing resistance patterns and also the evolving regulatory restrictions.

Country/Region-wise Acumens

Which region has most potential for growth of Animal Antibacterial And Antibiotics Market?

According to VMR analyst, The Asia-Pacific region's fast-increasing population and rising disposable incomes are driving up demand for animal protein, such as meat, dairy, and eggs. As a result, there is an increasing need to protect the health and production of livestock and poultry by using antibacterial and antibiotics to prevent and cure bacterial diseases.

Economic development in Asia-Pacific countries has resulted in increased intensive agricultural techniques and upgrading of livestock and poultry production systems. This tendency has raised the need for veterinary medications, such as antibacterial and antibiotics, to treat the health risks linked with intensive animal agriculture. The Asia-Pacific area is vulnerable to a variety of infectious illnesses affecting cattle and poultry, such as respiratory diseases, gastrointestinal infections, and vector-borne diseases. Climate variability, urbanization, and globalization all contribute to the development of animal illnesses, resulting in a high need for antibacterial and antibiotics for disease prevention and treatment.

Many nations in the Asia-Pacific area are launching measures to improve animal health and welfare, raise food safety requirements, and promote sustainable agriculture methods. This includes expenditures in veterinary infrastructure, R&D, and regulatory frameworks to guarantee that antibacterial and antibiotics are used responsibly in animal husbandry.

Which Region Dominates in Animal Antibacterial And Antibiotics Market?

North America has a well-established veterinary health infrastructure, including veterinary clinics, hospitals, and diagnostic laboratories equipped with advanced diagnostic and treatment equipment. This infrastructure supports the diagnosis, treatment, and prevention of bacterial infections in animals, increasing demand for antibacterial and antibiotics. For instance,

the World Health Organization

reports that animal origins account for 70% of newly discovered human diseases. Therefore, Ceva has a responsibility to stop these zoonotic illnesses as a veterinarian company. To present, more than fifty vaccinations have been developed to protect against 19 major zoonoses. Furthermore, more than 50% of Ceva's product line consists of vaccinations and other treatments for animal care.

North America has a large and diverse livestock and poultry industry, including beef, dairy cows, swine, poultry, and aquaculture. Operations Intensive agricultural practices in this region create a significant demand for antibacterial agents and antibiotics to maintain the health and productivity of animals raised for food production. North American regulatory agencies such as the US Food and Drug Administration (FDA) and the Canadian Food Agency. (CFIA) has strict standards and regulations regarding the approval, distribution, and use of veterinary drugs, including antibacterial drugs and antibiotics. Compliance with the law ensures the safety, effectiveness, and quality of veterinary medicines in the region.

North American consumers are very aware and concerned about food safety, animal welfare and the use of antibiotics in livestock production. As a result, demand for animal products from animals raised without antibiotics is increasing, which encourages the adoption of alternative therapies and consumer preferences for veterinary medicines, enabling the region to hold a dominant position in the market.

Competitive Landscape

The competitive landscape in the Animal Antibacterial And Antibiotics Market is dynamic and evolving, driven by changing customer preferences and market dynamics. Providers continue to innovate and differentiate their offerings to stay competitive and capture market share in this rapidly growing industry.

Some of the prominent players operating in the Animal Antibacterial And Antibiotics Market include:

Ashish Life Science, Merck Animal Health, Ayurvet, H. Boehringer Sohn AG & Co. KG., Ceva Sante Animale, Merial, Biogenesis Bago, Bayer HealthCare, Elanco, Endovac Animal Health., HIPRA, S.A., ECO Animal Health, HUVEPHARMA, Kyoritsuseiyaku Corporation, Dechra Pharmaceuticals, Neogen Corporation, Phibro Animal Health Corporation, UCBVET Animal Health and Welfare, Vetoquinol, Virbac, Zoetis.

Latest Developments

In February 2024, Elanco Animal Health Incorporated entered into an agreement to sell its aqua business to Merck Animal Health (NYSE:

MRK

) for around USD 1.3 Billion in cash, which is 7.4x the revenue of the Elanco aqua business estimated in 2023.

In July 2022, Boehringer Ingelheim, Evotec SE, and bioMerieux signed a joint venture agreement to develop the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance (AMR).

In May 2022, Ceva Sante Animale acquired Artemis Technologies, Inc., the Canadian oral rabies vaccine manufacturer. This acquisition will prove profitable as Ceva would be gaining control over the commercialization of ONRAB(R), a rabies glycoprotein recombinant oral vaccine.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Tetracyclines
• 5.3 Penicillins
• 5.4 Sulfonamides
• 5.5 Macrolides
• 5.6 Others

6 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET, BY ANIMAL TYPE

• 6.1 Overview
• 6.2 Companion Animals
• 6.3 Food-Producing Animals

7 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET, BY DELIVERY MODE

• 7.1 Overview
• 7.2 Oral Powder
• 7.3 Solutions Injections
• 7.4 Premix

8 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL ANIMAL ANTIBACTERIAL AND ANTIBIOTICS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Zoetis
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Merck Animal Health
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Merial
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Elanco
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Bayer HealthCare
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Biogenesis Bago
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 HUVEPHARMA
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Ceva Sante Animale
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Dechra Pharmaceuticals
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 ECO Animal Health
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research